The discovery that cancer can escape the cytotoxic capacity of T cells through checkpoint strategies has great potential to revolutionise the field of cancer therapeutics but, despite the clinical success of immune checkpoint inhibitors,60,61 T cells have received little attention in the context of NF1. The gene discussed is NF1; the disease is cancer.